secwatch.observer — SEC 8-K summary
======================================

Issuer:     Zoetis Inc. (ZTS)
CIK:        0001555280
Form:       8-K
Filed at:   2023-02-14T23:59:59+00:00
Accession:  0001555280-23-000072
Event type: earnings
Sentiment:  positive
Materiality: 0.75
Item codes: 2.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Zoetis Q4 revenue $2.0B (+9% operational); adj. EPS $1.15; FY23 guide $8.575-8.725B
--------------------------------------------------------------------------------

- Q4 revenue $2.0B (+4% reported, +9% operational); net income $461M ($0.99 EPS); adj. net income $539M ($1.15 adj. EPS).
- Full year 2022 revenue $8.1B (+4% reported, +8% operational); adj. net income $2.3B ($4.88 adj. EPS).
- U.S. segment revenue $1.112B (+7%), driven by Simparica Trio and dermatology brands Apoquel and Cytopoint.
- International segment revenue $901M (flat reported, +12% operational), led by parasiticides and dermatology.
- FY23 guidance: revenue $8.575-8.725B (6-8% operational growth); adj. diluted EPS $5.34-5.44.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1555280/000155528023000072/0001555280-23-000072-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1555280/000155528023000072/zts-20230214.htm
  HTML page:      https://secwatch.observer/filing/0001555280-23-000072

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer